NCT05033561View on ClinicalTrials.gov

Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants

PHASE3CompletedINTERVENTIONAL

Enrollment

905

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

May 24, 2022

Study Completion Date

October 25, 2022

Conditions

Poliomyelitis

Interventions

BIOLOGICAL

nOPV2

Novel Oral Poliomyelitis Type 2 Vaccine

Trial Locations (2)

Unknown

Clinica Cruz Jiminián, Santo Domingo

Hospital Universitario Maternidad Nuestra Señora de la Altagracia, Santo Domingo

Sponsors

Lead Sponsor

Fidec Corporation

All Listed Sponsors

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Fidec Corporation

OTHER